Sales & Marketing News | pharmaphorum

News

FDA starts review of BMS's 'celmod' for multiple myeloma

Bristol Myers Squibb could be months away from bringing the first 'celmod' to market, as the FDA starts a review of iberdomide for multiple myeloma.

News

NICE backs first disease-modifying drug for ARG1 deficiency

Immedica's Loargys is poised to become the first NHS therapy for ultra-rare genetic disorder ARG1 deficiency that can alter the course of the disease.

News

EU approval for new asthma drug Exdensur lifts GSK

EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.

News

UK seeks views on indefinite CE marks for medical devices

The UK has launched a consultation asking whether medical devices with CE marks issued in the EU and sold in GB should be recognised indefinitely.

News

FDA turns down 'national priority' drug from Disc Medicine

One of the beneficiaries of the FDA's national priority vouchers, Disc Medicine, has had its marketing application turned down by the regulator.

News

Bankruptcy threat looms as Quince runs out of options

Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out.

FDA starts review of BMS's 'celmod' for multiple myeloma

NICE backs first disease-modifying drug for ARG1 deficiency

EU approval for new asthma drug Exdensur lifts GSK

UK seeks views on indefinite CE marks for medical devices

FDA turns down 'national priority' drug from Disc Medicine

Bankruptcy threat looms as Quince runs out of options

FDA issues warning letters to five unapproved GLP-1 websites

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks